Clinical trialPhase 1 / Phase 2Completed
A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma
- Outcome
- Finished, no results posted
- Phase
- Phase 1 / Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- November 2012
- Expected end
- August 2017
- Enrollment
- 137 participants
- Sites
- 1
- Primary outcomes
- first cycle toxicity for phase I part; progression-free survival for phase II part, stage IV patients; resectability rate for phase II part, stage III patients
- Sponsor
- Other
- Results posted
- No
- Last update
- 1 September 2017
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 3
- Builds on itA randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally adv… DOI 10.1016/j.ejca.2018.07.007↗
- Builds on itNab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PAC… DOI 10.1016/s2468-1253(18)30196-1↗
- Builds on itPhase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresect… DOI 10.1038/bjc.2016.209↗